The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
NCT06378580
·
clinicaltrials.gov ↗
COMPLETED
Status
72
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Cancer
Interventions
DRUG:
Surufatinib combine immune checkpoint inhibitor
DRUG:
AG/FOLFIRINOX
Sponsor
Luo Cong